ViaLase Fires the First Commercial Shot in Laser Glaucoma Surgery

Glaucoma is the second leading cause of irreversible blindness in the world. It affects 76 million people today and is on course to reach 112 million by 2040. Most of those patients will spend years on topical eye drops before anything more interventional is considered, often waiting until the disease has already caused significant damage. That treatment gap, early-stage patients who are underserved by drops alone but not yet candidates for traditional surgery, is where a generation of minimally invasive glaucoma surgery devices have been competing for the past decade. On May 26, ViaLase added a new kind of instrument to that race: the first commercial femtosecond laser procedures for glaucoma, performed simultaneously in London and Dusseldorf.

The procedure is called FLIGHT, an acronym for Femtosecond Laser Image-Guided High-Precision Trabeculotomy. The ViaLuxe Laser System, which delivers it, pairs OCT imaging with a femtosecond pulse source to create precisely defined channels through the trabecular meshwork, the tissue that controls aqueous outflow and whose dysfunction is the root cause of most open-angle glaucoma. The key word in the press release is incision-free. No blade enters the eye. No implant is left behind. The femtosecond laser does the work entirely from outside, guided in real time by imaging. For photonics readers, the underlying technology is familiar: it is essentially the same approach that transformed cataract surgery a decade ago, now retargeted at the drainage angle.

The MIGS devices market is growing at a high single-digit to low double-digit compound annual growth rate depending on which analyst you consult, from roughly USD 1.8 billion in 2025 toward an expected USD 4.2 billion by 2035. The growth story is structural: aging populations, earlier diagnosis, and a physician base that has become increasingly comfortable recommending intervention before patients exhaust the medical therapy ladder. MIGS procedures now account for over 30% of surgical glaucoma interventions globally. The dominant players in that space are Glaukos, whose iStent family of trabecular microbypass stents owns a large share of the market, and Alcon, whose Hydrus microstent competes directly. Both require a blade incision to implant a device. That is the opening ViaLase is targeting.

The laser-based segment of glaucoma surgery is more fragmented. Selective laser trabeculoplasty has been a first-line option for years, using a 532-nm nanosecond laser to stimulate the trabecular meshwork rather than ablate it. Alcon acquired Belkin Vision and its DSLT technology specifically to compete here. Elios Vision, now part of Bausch + Lomb, uses an excimer laser to create microchannels ab interno during cataract surgery. What ViaLase offers is different from both: non-contact, non-incisional, guided by real-time OCT, and usable as a standalone procedure rather than only as a cataract surgery add-on. In the 2026 glaucoma pipeline catalogued by Glaucoma Today, FLIGHT is listed as the only femtosecond laser procedure approved outside the United States.

ViaLase has launched in Europe under CE mark and is simultaneously running a US IDE clinical trial. That two-track structure is standard for ophthalmic devices seeking eventual FDA clearance, but it means the US market, the largest single geography in MIGS, remains closed for now. The European launch is supported by a focused distributor network, including an exclusive agreement with Carleton Optical in the United Kingdom. Professor Gus Gazzard, Director of Surgery at Moorfields Eye Hospital and one of the first commercial FLIGHT users, described the level of visualization and procedural precision as particularly impressive. Sheraz Daya, founder of Centre for Sight in London and the other first-adopter surgeon, called the procedure a redefinition of glaucoma care. Both are established opinion leaders in European ophthalmology, and their early endorsement carries meaningful weight for adoption.

The questions that remain open are the ones that any new glaucoma device faces. Durability is the central one. ViaLase has cited preliminary data showing that the trabecular opening created by the femtosecond laser stays patent for years, and the incision-free approach theoretically reduces the fibrotic healing response that closes channels created by blade-based techniques. But long-term data from randomized controlled trials at commercial scale does not yet exist. Reimbursement in European markets is the other variable: without favorable coding, even compelling procedural data does not translate into volume.

From a photonics industry perspective, the ViaLase launch is a reminder that femtosecond laser technology continues to open new clinical markets. Refractive surgery was the first. Cataract surgery was the second, and it built a substantial equipment market around companies like Alcon, Johnson and Johnson Vision, and Ziemer. Glaucoma is the third application, and if FLIGHT achieves clinical adoption at meaningful scale, it represents a recurring capital equipment opportunity in ophthalmology practices and surgical centers that are already femtosecond-equipped for cataract work. The ViaLuxe system is not a repurposed cataract laser; it is a purpose-built instrument. But the clinical infrastructure and physician familiarity with femtosecond docking procedures is already in place across the target customer base. That lowers the adoption barrier considerably. The companies that supply pulse sources, optical parametric components, and beam delivery systems to the medical device sector will be watching this commercial launch closely.